Sign in

CIK 0001671858

  • Non-accelerated filer
  • Smaller reporting company

ARS Pharmaceuticals, Inc.

Sign in to watch
Ticker
SPRY
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
811489190
Phone
+1 858-771-9307
Business address
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130
Former names
Silverback Therapeutics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2024-01-02 Lowenthal Richard E President and CEO Grant or award · Stock option (right to buy) +880,000 880,000
2024-01-02 Lowenthal Richard E President and CEO Grant or award · Stock option (right to buy) +300,000 300,000
2024-01-02 Karas Eric Chief Commercial Officer Grant or award · Stock option (right to buy) +200,000 200,000
2024-01-02 Tanimoto Sarina Chief Medical Officer Grant or award · Stock option (right to buy) +300,000 300,000
2024-01-02 Tanimoto Sarina Chief Medical Officer Grant or award · Stock option (right to buy) +880,000 880,000
2024-01-02 Dorsey Brian Chief Operating Officer Grant or award · Stock option (right to buy) +350,000 350,000
2024-01-02 Chakma Justin Chief Business Officer Grant or award · Stock option (right to buy) +350,000 350,000
2024-01-02 Scott Kathleen D. Chief Financial Officer Grant or award · Stock option (right to buy) +200,000 200,000
2024-01-02 Fitzpatrick Alexander A Chief Legal Officer Grant or award · Stock option (right to buy) +300,000 300,000
2023-09-29 Fitzpatrick Alexander A Chief Legal Officer Purchase +46,258 $3.78 $175K 89,227
2023-09-28 Fitzpatrick Alexander A Chief Legal Officer Purchase +40,000 $3.62 $145K 42,969
2023-09-21 RA CAPITAL MANAGEMENT, L.P. Director Purchase +2,508,691 $2.97 $7.5M 8,365,465
2023-09-21 RA CAPITAL MANAGEMENT, L.P. Director Purchase +191,309 $3.83 $733K 8,556,774
2023-09-01 Shawver Laura Director Exercise or conversion 10b5-1 +2,997 $1.27 $4K 213,343
2023-09-01 Shawver Laura Director Exercise or conversion 10b5-1 +97,003 $1.27 $123K 310,346
2023-09-01 Shawver Laura Director Sale 10b5-1 −100,000 $7.71 $771K 210,346
2023-09-01 Shawver Laura Director Exercise or conversion · Stock Option (Right to Buy) 10b5-1 −2,997 0
2023-09-01 Shawver Laura Director Exercise or conversion · Stock Option (Right to Buy) 10b5-1 −97,003 55,235
2023-08-29 RA CAPITAL MANAGEMENT, L.P. Director Purchase +3,750,000 $6.20 $23.3M 5,856,774
2023-08-29 ORBIMED ADVISORS LLC Director Purchase +500,000 $6.20 $3.1M 8,019,187

Page 20 of 31 · 602 trades